s6y

Polaryx Therapeutics, Inc.

Ticker
PLYX
CIK
2075320
Industry
Pharmaceutical Preparations

Financials 4

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025

News 5

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing

Ownership 9

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities
  7. 3 Initial statement of beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities

Prospectus 7

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  3. S-1/A General form of registration statement for all companies including face-amount certificate companies
  4. S-1/A General form of registration statement for all companies including face-amount certificate companies
  5. S-1 General form of registration statement for all companies including face-amount certificate companies
  6. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  7. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Proxies 2

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements

Other 9

  1. ARS Annual report to security holders
  2. SCHEDULE 13D
  3. EFFECT Notice of Effectiveness
  4. CERT Certification by an exchange approving securities for listing
  5. 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
  6. C-U Progress Update
  7. C-U Progress Update
  8. C/A Offering Statement
  9. C Offering Statement